Antioxidant Vitamins

The food works. The pill does not.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you have read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not to replace medical care.

Safety note: Current and former smokers should avoid beta-carotene supplements. Two large randomized trials (ATBC and CARET) found increased lung cancer incidence and total mortality, and CARET was stopped early because of harm. (3,4) The U.S. Preventive Services Task Force recommends against beta-carotene supplements for cardiovascular or cancer prevention, and anyone who smokes or has smoked and is taking one can discuss stopping it with their physician.

In brief: Eating antioxidant-rich foods consistently associates with lower cardiovascular risk; taking antioxidant vitamin supplements does not, and in specific high-risk populations the supplements caused harm. (1,2,3,4,5,6,7,8) Vitamin E supplementation showed no cardiovascular benefit across multiple large trials (1,2,5,6) and a mortality signal at doses of 400 IU or more daily. (7) Beta-carotene increased lung cancer incidence and total mortality in smokers and asbestos-exposed workers — both trials were stopped or completed with positive harm findings. (3,4) Vitamin C produced consistent null results. (6,14) The biology of oxidative stress is real, but the cardiovascular benefit tracks with whole-food dietary patterns rather than the isolated antioxidant compounds extracted from them. (9)

Introduction

For two decades, antioxidant vitamins were a leading hypothesis in cardiovascular prevention, supported by consistent observational data and a well-established biological mechanism.

The biology was textbook. Reactive oxygen species damage LDL cholesterol; oxidized LDL is the form macrophages take up to become foam cells; foam cells are the cellular foundation of early atherosclerosis. Antioxidants neutralize reactive oxygen species. Vitamin E sits in LDL particles and cell membranes precisely to protect them from oxidation. The mechanism worked in cell culture, in animals, and in population studies of people who ate antioxidant-rich diets. The 1996 CHAOS trial — a small early study in 2,002 patients with coronary disease — appeared to show a 77% reduction in non-fatal myocardial infarction with vitamin E. (11)

Then the larger trials arrived.

HOPE, HOPE-TOO, GISSI-Prevenzione, the Women’s Health Study, and Physicians’ Health Study II — together representing hundreds of thousands of patient-years of vitamin E supplementation — found no reduction in cardiovascular events. (1,2,5,6,12) The Miller 2005 meta-analysis pooled 19 trials and 135,967 participants and found that high-dose vitamin E (≥400 IU daily) was associated with increased all-cause mortality. (7) The Cochrane antioxidant review reached similar conclusions. (8)

Beta-carotene was worse. ATBC and CARET tested it in smokers and asbestos-exposed workers — populations with the highest oxidative burden, where the antioxidant hypothesis predicted the largest benefit. Both trials found that beta-carotene supplementation increased lung cancer incidence and overall mortality. (3,4) CARET was stopped 21 months early because of harm. The same compound that correlated with lower cancer risk in observational studies caused more cancer in smokers.

The trials dismantled the idea that the extractable antioxidant compounds in those foods were the active ingredient. The Mediterranean diet — high in fruits, vegetables, olive oil, and nuts — reduces cardiovascular events when tested in a randomized trial. (9) The isolated antioxidant compounds extracted from those foods, concentrated to high doses, and delivered as pills do not. Whatever the dietary pattern is doing for cardiovascular health, the extractable antioxidants are not what is doing it.

Consider the comparison directly. An orange contains vitamin C, but it also contains fiber, water, hundreds of plant compounds, and a sweetness that tends to replace a cookie rather than sit alongside one. A 1,000 mg vitamin C tablet contains none of that. The orange and the tablet share a single molecule. They are not the same exposure.

Where the Evidence Stands

For antioxidant supplements and cardiovascular prevention, the evidence has been tested at the level that matters most, and it is not merely negative. Vitamin E was tested across hundreds of thousands of patient-years and produced no benefit, with a mortality signal at high doses. (1,2,5,6,7) Beta-carotene did not simply fail; it increased lung cancer and total mortality in smokers, in trials stopped early for harm. (3,4) The favorable evidence belongs to whole-food dietary patterns, not extracted compounds: a Mediterranean diet reduced cardiovascular events in a randomized trial. (9) This describes what the trials found; it is information for a conversation with a clinician, not a basis for self-directed treatment.

Find Your Situation

The table identifies what the evidence supports for specific profiles. Each entry is examined in the sections that follow.

Oxidative Stress and Atherosclerosis: Why the Theory Was Compelling

The oxidative stress hypothesis was not invented to sell supplements. It was built on biology that remains correct. (10)

Reactive oxygen species damage cellular components — lipids, proteins, DNA. Native LDL is not particularly atherogenic. Oxidized LDL is avidly taken up by macrophages through scavenger receptors, transforming them into foam cells, the cellular foundation of early atherosclerotic plaque. Oxidative stress impairs nitric oxide signaling, reducing the artery’s ability to dilate. Oxidized LDL triggers inflammatory responses that accelerate plaque development and may destabilize the fibrous cap, increasing rupture risk. (10)

Oxidative stress is a real feature of atherosclerosis. The trials tested whether it was driving the disease or merely reflecting it — and the evidence suggests it is largely a consequence, or that the upstream drivers of both oxidative stress and atherosclerosis are not addressable by supplementing isolated antioxidants.

The observational evidence amplified the biological case. Mediterranean and plant-rich diets high in natural antioxidants consistently associated with lower cardiovascular risk. Blood levels of vitamin E, vitamin C, and carotenoids correlated with fewer cardiovascular events in population studies. Animal models showed antioxidants slowing atherosclerosis and protecting LDL from oxidation.

CHAOS (1996) added apparent clinical confirmation — a 77% reduction in non-fatal MI in 2,002 patients with angiographic coronary disease, randomized to vitamin E (400 or 800 IU daily) and followed for a median of 510 days. (11) Two cautions accompany that figure. First, the reduction was confined to non-fatal MI; cardiovascular and total mortality were not reduced, and cardiovascular deaths were numerically higher in the vitamin E group. Second, endpoints were not adjudicated by methods that would meet modern trial standards. The result nonetheless drove enormous enthusiasm and shaped a decade of supplement use before the larger trials told a different story.

Vitamin E: The Most Rigorously Tested Antioxidant

Vitamin E received the most rigorous testing of any antioxidant. The alpha-tocopherol form is the body’s primary fat-soluble antioxidant, incorporated into LDL particles and cell membranes to protect them from oxidation. If any antioxidant supplement should have worked, vitamin E had the strongest theoretical case.

HOPE (2000). 9,541 high-risk patients (vascular disease or diabetes plus an additional risk factor) randomized to vitamin E 400 IU daily or placebo for a mean of 4.5 years. The primary cardiovascular composite — MI, stroke, or cardiovascular death — occurred in 16.2% of the vitamin E group versus 15.5% on placebo (relative risk 1.05, 95% CI 0.95–1.16). (1) No reduction in events or mortality.

HOPE-TOO (2005). Extended follow-up to a median of 7 years total. Still no cardiovascular benefit. The vitamin E group showed an increase in heart failure (relative risk 1.13, 95% CI 1.01–1.26, P=0.03) and heart failure hospitalizations (relative risk 1.21, 95% CI 1.00–1.47, P=0.045). (2) Patients with heart failure at baseline had been excluded from the trial, so these represented new-onset cases.

GISSI-Prevenzione (1999). 11,324 post-MI patients randomized in a factorial design to vitamin E 300 mg/day, n-3 PUFA 1 g/day, both, or neither, for 3.5 years. Vitamin E did not reduce cardiovascular events. (12) The omega-3 arm showed a significant benefit — confirming that the null result for vitamin E in the same large trial was not a problem of statistical power.

Women’s Health Study (2005). 39,876 healthy women randomized to vitamin E 600 IU every other day for 10 years. The primary composite of major cardiovascular events was not reduced (relative risk 0.93, 95% CI 0.82–1.05), and total mortality was unchanged. (5) A secondary analysis did show a significant 24% reduction in cardiovascular death (relative risk 0.76); Physicians’ Health Study II did not reproduce that signal, and it is best read as hypothesis-generating. (5,6)

Physicians’ Health Study II (2008). 14,641 male physicians randomized to vitamin E 400 IU every other day for 8 years. No cardiovascular benefit. (6)

Miller 2005 mortality meta-analysis. Pooling 19 randomized trials with 135,967 participants, this Annals of Internal Medicine analysis found that high-dose vitamin E (≥400 IU daily for at least one year) was associated with increased all-cause mortality. (7) The pooled risk difference at the high doses was 39 additional deaths per 10,000 persons (relative risk 1.04, 95% CI 1.01–1.07). Lower doses were not associated with increased mortality, and no dose was associated with benefit. The finding was debated in subsequent meta-analyses, but no later analysis demonstrated cardiovascular benefit, and the signal toward harm at higher doses has been broadly accepted.

Cochrane antioxidant review (2012). A systematic review of antioxidant supplements (vitamins A, C, E, beta-carotene, selenium) for prevention of mortality found that beta-carotene, vitamin A, and vitamin E supplementation may increase mortality. (8)

No major guideline recommends vitamin E supplementation for cardiovascular prevention. The U.S. Preventive Services Task Force explicitly recommends against vitamin E supplements for this purpose (a Grade D recommendation), and the American Heart Association does not recommend antioxidant supplements, advising instead that antioxidants be obtained from food.

Beta-Carotene: The Supplement That Caused Harm

Beta-carotene’s story is more troubling than vitamin E’s. A supplement taken to prevent disease increased disease incidence in the populations at highest theoretical benefit.

Higher blood levels of beta-carotene consistently associated with lower cardiovascular and cancer risk in observational studies. The antioxidant mechanism was well-characterized. The case for testing in smokers — whose lungs experience continuous oxidative damage — looked compelling.

ATBC (1994). 29,133 Finnish male smokers (age 50–69, smoking ≥5 cigarettes daily) randomized to beta-carotene 20 mg daily, vitamin E 50 mg, both, or placebo for an average of six years. Beta-carotene increased lung cancer incidence by 18% (relative risk 1.18, 95% CI 1.03–1.36) and total mortality by 8% (relative risk 1.08), primarily from lung cancer and ischemic heart disease deaths. (3) The trial result reversed the protective association seen in observational studies.

CARET (1996). 18,314 smokers and asbestos-exposed workers randomized to beta-carotene 30 mg plus retinyl palmitate 25,000 IU or placebo. The active intervention group had a 28% increase in lung cancer incidence, a 17% increase in deaths, and a higher rate of cardiovascular disease mortality compared with placebo. (4) The trial was stopped 21 months early because of harm.

The U.S. Preventive Services Task Force recommends against beta-carotene supplementation for prevention of cardiovascular disease or cancer. Beta-carotene from food sources (carrots, sweet potatoes, leafy greens) does not appear to carry this risk and remains part of healthy dietary patterns. The original Physicians’ Health Study found no cardiovascular benefit or harm from beta-carotene in a general male population — in contrast to the all-smoker ATBC and CARET cohorts — over 12 years. (13) A compound that showed harm in high-risk populations and no benefit in general populations is not supported for cardiovascular prevention.

At the high doses found in supplements, beta-carotene in smokers’ lungs may stop neutralizing free radicals and start generating them. The exact mechanism remains debated. The clinical signal does not.

Vitamin C: Less Tested, Same Answer

Vitamin C received less extensive testing than vitamin E but produced consistent null results.

Physicians’ Health Study II found no reduction in cardiovascular events with vitamin C 500 mg daily over 8 years. (6) The Women’s Antioxidant Cardiovascular Study, which tested vitamin C, vitamin E, and beta-carotene in 8,171 women at high cardiovascular risk, found no cardiovascular benefit from any of the three. (14) Meta-analyses of vitamin C supplementation trials consistently find no reduction in cardiovascular events.

Some short-term trials show modest blood pressure reductions with high-dose vitamin C. This has not translated into cardiovascular event reduction in any trial conducted.

Food sources of vitamin C associate with cardiovascular benefit in observational data — but the broader antioxidant experience strongly suggests the benefit comes from the whole food, not the isolated compound.

The Evidence at a Glance

The pattern across the evidence is consistent. Antioxidant supplementation did not reduce major cardiovascular events in the primary analysis of any large trial, regardless of dose or population. Antioxidant-rich dietary patterns did, when tested in a randomized trial.

Why the Hypothesis Failed: The Food-Supplement Distinction

Dietary patterns work. Isolated supplements do not. Why the divergence exists is partly unresolved, but several explanations are well supported.

The food matrix is not reproducible in a capsule. A Mediterranean diet reduced cardiovascular events in PREDIMED. (9) Whole foods contain thousands of compounds — vitamins, minerals, fiber, polyphenols, carotenoids, flavonoids, and more — in natural combinations and at physiological concentrations. Isolating one or two compounds, concentrating them to pharmacological doses, and delivering them as pills produces a fundamentally different exposure. Antioxidant-rich foods are also typically high in fiber, low in refined carbohydrates and processed fats, and consumed in patterns that displace less healthy foods. Pulling one antioxidant out and putting it in a capsule strips that entire context.

Dose matters in ways the original hypothesis underestimated. Supplemental vitamin E doses of 400–800 IU are many times typical dietary intake, and supplemental beta-carotene is far above what fruits and vegetables provide. At those concentrations the chemistry can reverse: antioxidants become pro-oxidants, generating the very damage they were meant to prevent. (3,4) Reactive oxygen species are not purely harmful — they serve essential signaling functions in cell-cycle regulation, immune defense, and apoptosis. Blocking them broadly with high-dose supplementation may disrupt beneficial processes more than it protects against harmful ones.

Oxidative stress may be a consequence rather than a cause. Atherosclerotic plaques generate oxidative stress. Treating oxidative stress with antioxidants, without addressing the upstream drivers of plaque formation, may be treating a downstream marker rather than the disease.

What the Evidence Actually Supports

For cardiovascular benefit, the evidence supports whole-food dietary patterns, not isolated antioxidant supplements.

A Mediterranean or plant-rich dietary pattern. PREDIMED — retracted in 2018 over randomization irregularities and republished the same year with reanalyzed data — found that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events by about 30% (hazard ratios 0.70 and 0.72) in 7,447 adults at high cardiovascular risk over a median of 4.8 years. (9) The republished analysis, which corrected the randomization problems, reached the same conclusion as the original. Whole-food patterns rich in fruits, vegetables, legumes, fish, nuts, and olive oil are supported by both observational and randomized trial evidence.

Eating fruits and vegetables. The 2020–2025 U.S. Dietary Guidelines recommend at least 2.5 cups of vegetables and 2 cups of fruit daily for adults, supported by extensive observational evidence and by the dietary trials.

Antioxidant intake from food, not capsules. Food sources deliver vitamin E in the context of unsaturated fats and fiber, vitamin C with bioflavonoids and other plant compounds, and carotenoids in the natural combinations found across dozens of plant forms. Supplements deliver isolated compounds at pharmacological doses, and the trial evidence does not support that approach. (1,2,3,4,5,6,7,8) The evidence favors a whole-food dietary pattern — more fruits, vegetables, nuts, and olive oil — with any decision about supplements directed to a clinician rather than to a vitamin the trials have already tested and found wanting.

Two Patients, Same Supplement Aisle, Different Answers

Both profiles below are composites built from the populations studied in the trials this article reviews.

Patient A: A 58-year-old woman who eats a Mediterranean-style diet — fruit and yogurt for breakfast, salad with olive oil for lunch, fish or legumes most evenings, nuts as snacks. Her physician has not recommended any antioxidant supplements. She wonders whether she should add a high-dose vitamin E or a “heart antioxidant blend” she has seen advertised.

She is already receiving the intervention the evidence supports. (9) The Mediterranean pattern is what reduced cardiovascular events in PREDIMED, and it does so by delivering antioxidants in their natural food matrix — alongside fiber, monounsaturated fats, polyphenols, and the displacement of less healthy foods. Adding a high-dose antioxidant supplement on top of that diet would not enhance the benefit; it would introduce pharmacological concentrations of isolated compounds that the trials show provide no additional cardiovascular protection (1,2,5,6) and, at doses ≥400 IU daily for vitamin E, carry a small mortality signal. (7) The evidence points toward keeping the diet that works and skipping the capsules that do not.

Patient B: A 64-year-old man, current smoker (a pack a day for 30 years), with elevated LDL and a family history of lung cancer. A wellness website recommended a high-dose antioxidant blend — beta-carotene 25 mg, vitamin E 400 IU, vitamin C 1,000 mg daily — to “protect” his lungs and heart from smoking damage. He started it three weeks ago.

This is the closest match the supplement literature has to actively dangerous in a specific population. ATBC and CARET tested beta-carotene in current and former smokers, and both found increased lung cancer incidence and increased mortality. (3,4) CARET was stopped early because of harm. The vitamin E component carries the mortality signal at this dose from the Miller meta-analysis. (7) For someone who smokes, this combination is the clearest signal to stop that the supplement evidence produces — not “uncertain,” not “unproven,” but tested, harmful, and halted. The defensible step is to stop the supplement and to prioritize, with his physician, the intervention that would actually reduce his lung cancer and cardiovascular risk: smoking cessation, with whatever pharmacologic and behavioral support is available.

Common Misconceptions

“Antioxidants from supplements are the same as antioxidants from food.” The trial evidence directly demonstrates they are not. The food works; the supplement does not, and in some populations it causes harm. (3,4) Supplement doses of vitamin E are many times typical dietary intake, and the dietary pattern carries fiber, polyphenols, the displacement of less healthy foods, and synergistic compounds the capsule cannot replicate.

“Higher doses of antioxidants must be more protective.” The Miller 2005 meta-analysis tested this directly. Higher doses of vitamin E (≥400 IU daily) were associated with higher all-cause mortality; the dose-response trend ran in the wrong direction. (7) At high doses, antioxidants can flip into pro-oxidants and interfere with the cell-signaling roles that reactive oxygen species normally serve.

“Beta-carotene is just a precursor to vitamin A — it has to be safe.” Not in smokers. Two large randomized trials (ATBC and CARET) found increased lung cancer and total mortality with beta-carotene supplementation in current and former smokers. (3,4) Beta-carotene from food sources does not appear to carry this risk; supplemental beta-carotene at pharmacological doses in smokers does.

“The CHAOS trial showed vitamin E reduces heart attacks.” CHAOS (1996) showed an apparent 77% reduction in non-fatal MI in 2,002 patients — but with no reduction in cardiovascular or total mortality, and by methods that would not meet modern adjudication standards. (11) The result was not replicated in HOPE, HOPE-TOO, GISSI-Prevenzione, the Women’s Health Study, or Physicians’ Health Study II. (1,2,5,6,12) Single-trial findings, especially in small early trials, require independent replication.

“Vitamin E prevents heart failure.” It does the opposite. HOPE-TOO found that long-term vitamin E supplementation increased the risk of new heart failure (RR 1.13) and heart failure hospitalizations (RR 1.21). (2)

“Antioxidant blends combine the best of multiple vitamins.” The Cochrane meta-analysis found no mortality benefit and possible harm with vitamin A, beta-carotene, and vitamin E. (8) Combination products do not solve the problem of isolated antioxidants at pharmacological doses; they multiply it.

The Bottom Line

Oxidative stress contributes to atherosclerosis. (10) Dietary patterns rich in antioxidants protect cardiovascular health. (9) Neither fact means that supplementing isolated antioxidants at pharmacological doses prevents cardiovascular disease. Vitamin E showed no benefit and a mortality signal at high doses. (1,2,7) Beta-carotene increased lung cancer and total mortality in smokers. (3,4) Vitamin C produced consistent null results. (6,14)

The evidence favors antioxidants from food rather than from supplements, consistent with the position of the major guidelines. The food and the capsule are not the same exposure.

Article 18 turns to coenzyme Q10 — a supplement with a more nuanced evidence base, where the question is not whether the biology is real but whether the trial signals are large enough, and consistent enough, to act on.

Key Terms

Alpha-tocopherol: The primary biologically active form of vitamin E and the body’s main fat-soluble antioxidant. Supplementation has not demonstrated cardiovascular benefit and carries a mortality signal at doses ≥400 IU daily.

Beta-carotene: A precursor to vitamin A and a dietary antioxidant. Supplementation increased lung cancer incidence and total mortality in randomized trials in smokers, leading those trials to be stopped or to report harm.

LDL oxidation: Chemical modification of LDL cholesterol by reactive oxygen species, producing a more atherogenic form that macrophages engulf to form foam cells. Antioxidants prevent this in test tubes but not in clinical outcome trials.

Oxidative stress: An imbalance between free radical production and antioxidant defenses. A real feature of atherosclerosis — likely more consequence than cause in established disease.

PREDIMED: Spanish randomized trial that found a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduces cardiovascular events. Retracted and republished in 2018 after randomization irregularities were corrected; the reanalysis reached the same conclusion. The strongest randomized trial evidence for whole-food dietary patterns in cardiovascular prevention.

Pro-oxidant effect: The paradoxical capacity of antioxidants to generate free radicals rather than neutralize them at high concentrations or in specific cellular environments. Proposed as a mechanism for beta-carotene’s harm in smokers.

Reactive oxygen species (ROS): Molecules, including free radicals, that can damage cellular components but also serve essential signaling functions. Blocking them broadly with high-dose antioxidant supplementation may disrupt beneficial processes alongside harmful ones.

Vitamin C (ascorbic acid): The body’s primary water-soluble antioxidant. Supplementation does not reduce cardiovascular events in randomized trials.

References

1. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients: the HOPE Trial. N Engl J Med. 2000;342(3):154–160.
2. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: the HOPE-TOO trial. JAMA. 2005;293(11):1338–1347.
3. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers (ATBC). N Engl J Med. 1994;330(15):1029–1035.
4. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (CARET). N Engl J Med. 1996;334(18):1150–1155.
5. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study. JAMA. 2005;294(1):56–65.
6. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300(18):2123–2133.
7. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46.
8. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;(3):CD007176.
9. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED). N Engl J Med. 2018;378(25):e34. (Corrected and republished from N Engl J Med. 2013;368(14):1279–1290.)
10. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84(4):1381–1478.
11. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347(9004):781–786.
12. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447–455.
13. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334(18):1145–1149.
14. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: the Women’s Antioxidant Cardiovascular Study (WACS). Arch Intern Med. 2007;167(15):1610–1618.

HeartBuddi • Your heart. Own it. • This article is educational and is not a substitute for individualized medical advice.